Document is current
Any future updates will be listed below
-
Authors
Zhang, Qiong
Chao, Ti‐Chun
Patil, Veena S
Qin, Yue
Tiwari, Shashi Kant
Chiou, Joshua https://orcid.org/0000-0002-4618-0647
Dobin, Alexander
Tsai, Chih‐Ming
Li, Zhonghan
Dang, Jason
Gupta, Shagun
Urdahl, Kevin
Nizet, Victor https://orcid.org/0000-0003-3847-0422
Gingeras, Thomas R
Gaulton, Kyle J
Rana, Tariq M https://orcid.org/0000-0001-9558-5766
-
Funding
Funding for this research was provided by:
HHS|NIH|National Cancer Institute (CA177322)
HHS|NIH|National Institute on Drug Abuse (DP1DA039562)
HHS|NIH|National Institute on Drug Abuse (DA046171)
NIAID (AI125103)
- License Information
-
More Information
Article History
Received: 13 June 2018
Revised: 12 February 2019
Accepted: 14 February 2019
First Online: 27 March 2019
Conflict of interest
: TMR is a founder of ViRx Pharmaceuticals and a member of its scientific advisory board. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.
